αGalCer-RBD
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain
Product Specifications
UNSPSC
12352005
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/αgalcer-rbd.html
Solubility
10 mM in DMSO
Smiles
O[C@H]1[C@H]([C@H](O[C@@H]([C@@H]1O)OC[C@@H]([C@@H]([C@@H](CCCCCCCCCCCCCC)O)O)NC(C#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC)=O)CNC(COCCOCCOCCNC(CON)=O)=O)O.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]
Molecular Formula
C60H118N4O14
Molecular Weight
1119.60
References & Citations
[1]Wang J, et al. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J Med Chem. 2022;65 (3) :2558-2570.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RC217217L1V 200 µL
Lenti ORF particles, TXNRD1 (Myc-DDK-tagged)-Human thioredoxin reductase 1 (TXNRD1), transcript variant 2, (Note, selenocystein protein, internal
Sign In for Pricing
View Details MBS6362679-01 0.2 mL
VN1R5, ID (VN1R5, V1RL5, Vomeronasal type-1 receptor 5, G-protein coupled receptor GPCR26, V1r-like receptor 5) (Azide free) (HRP)
Sign In for Pricing
View Details MBS6362679-02 5x 0.2 mL
VN1R5, ID (VN1R5, V1RL5, Vomeronasal type-1 receptor 5, G-protein coupled receptor GPCR26, V1r-like receptor 5) (Azide free) (HRP)
Sign In for Pricing
View Details